← Back

Wire · operational-macro

Ascletis Submits FDA IND for ASC30_39 Oral Obesity Combination

Published

17 November 2026

Topic

operational-macro

◆ Sectors

Drug Discovery

◆ Geography

United States

◆ Source

Read at patientcareonline.com →

◆ Verified

Fusion42 · 17 November 2026 · Fusion42 review

Ascletis has submitted an investigational new drug (IND) application to the US FDA for ASC30_39, a once-daily oral fixed-dose combination of a GLP-1 receptor agonist and a selective amylin receptor agonist for obesity, backed by preclinical data but without human efficacy or safety results reported.

This Wire brief sits within Fusion42's coverage of Drug Discovery, and 2 sources have reported it between 11 Nov 2026 and 17 Nov 2026.

◆ ◆ The Wire takeaway

Your oral obesity drug's path now officially passes a key FDA gate which opens early validation but demands human trial evidence soon. This is your chance to shape future weight management options before competitors lock in their claims.

◆ Coverage

2 sources · first reported 11 Nov 2026 · latest 17 Nov 2026

◆ Related on Wire

◆ Topics

Drug DiscoveryFDAIND-submissionoral-obesity-drugGLP-1amylinpreclinical-data